Quadruple dose tested in fight against tuberculosis

NCT ID NCT06057519

Recruiting now Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

Summary

This study is testing if a much higher daily dose of the antibiotic rifampicin is safe and works better for treating lung tuberculosis than the standard dose. Researchers will compare the two doses in 164 adult patients to see if the higher dose causes more liver problems or side effects, and if it helps cure patients faster. The goal is to find the most effective and safest dose to control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ASL Città di Torino
RECRUITING

Turin, Italy
Radboud University Medical Centre
RECRUITING

Nijmegen, Netherlands

Contact

Conditions

Explore the condition pages connected to this study.

TUBERCULOSIS, PULMONARY